Detalles de la búsqueda
1.
Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.
Biol Blood Marrow Transplant
; 23(8): 1295-1302, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28412518
2.
Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Biol Blood Marrow Transplant
; 18(7): 1128-35, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22248715
3.
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
Hematol Oncol
; 29(4): 202-10, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21360728
4.
Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.
J Clin Oncol
; 31(35): 4416-23, 2013 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24166529
5.
Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
Hematol Oncol Stem Cell Ther
; 4(4): 149-56, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22198185
Resultados
1 -
5
de 5
1
Próxima >
>>